Oncology Corporate Profile
Apogenix develops protein therapeutics that could transform the treatment of life-threatening diseases by targeting critical pathways involved in the growth, migration, and apoptosis of diseased cells. The company's lead drug candidate APG101 is currently being evaluated in patients with glioblastoma ' a disease with a tremendous need for new and effective therapies.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|Apocept™ / APG101||CD95 ligand inhibitor||Glioblastoma Multiforme (GBM)||II|
|Apocept™ / APG101||CD95 ligand inhibitor||Myelodysplastic Syndrome (MDS)||I|
|Apocept™ / APG101||CD95 ligand inhibitor||Various cancer types||I|
View additional information on product candidates here »